CD Capital Portfolio Highlights: October 2024 Innovations and Milestones

According to the "Detailed Rules for the Implementation of the Management of the Gradient Cultivation of High-quality Small and Medium-sized Enterprises in Shanghai" (HJXGF [2022] No. 8), after expert review and comprehensive evaluation, the 2024 list of specialized, refined, distinctive, and innovative small and medium-sized enterprises in Shanghai (second batch) has been announced. Enlight Medical Limited has obtained the certification as a "specialized, refined, distinctive, and innovative small and medium-sized enterprise."

The title of "Specialized, Precise, Unique, and Innovative Enterprise" awarded by Shanghai Municipality this time is an affirmation of Enlight Medical's dedication to a specific niche market, achieving a development path that is professional, meticulous, distinctive, and innovative, building upon the foundation of high-tech enterprises.

At the same time, Synxess, a wholly-owned subsidiary of Enlight Medical, Shenzhen Xinyi Medical Device Co., Ltd.^®Neurovascular Microguidewire Receives Registration Approval from Guangdong Provincial Medical Products Administration. This is the second new product registration certificate granted to Enlight Medical this year.

This neurovascular micro-guidewire utilizes a unique patented polymer impregnation technology, filling the gap between the coil and the core with polymer resin, significantly enhancing the torque control of the micro-guidewire. The integrated coil and core structure allows torque control to be directly transmitted to the distal tip by hand. Additionally, the guidewire tip has a hardness of 0.8gf, presenting a low risk of perforation, strong shape retention, durability without deformation. The stainless steel core provides excellent pushability and support, while a high-quality PTFE coating formula ensures low push resistance. This product is used in the treatment or diagnosis of cerebrovascular conditions, assisting in the establishment of intravascular pathways when used with microcatheters or other interventional devices.

Enlight Medical will continue to adopt a model that combines independent research and development with the introduction of overseas technologies, using technological innovation as the core driving force to create high-quality products, accumulate brand reputation, actively integrate into China's "Made in China" strategic plan, base itself in China while facing the world, be guided by clinical needs, and continuously serve the cause of human health.

Recently, Intalight's DREAM OCT (DREAM OCT) has been installed and used at the Doheny Eye Institute of the University of California, Los Angeles (UCLA) in the United States, a globally renowned ophthalmic research institution with a 77-year long history.

Founded in 1947, the Doheny Eye Institute is one of the leading vision research institutions in the United States and was ranked fifth among the best ophthalmic hospitals nationwide in 2024. The team of Professor SriniVas R. Sadda, internationally renowned ophthalmology expert, former president of the Doheny Eye Institute, director of Artificial Intelligence and Imaging Research, and faculty member at UCLA's Geffen School of Medicine, has already put this device into academic research use.

In the past two years, Intalight has been continuously expanding its global presence with breakthrough progress. Currently, it has established research collaborations with over 20 top-tier ophthalmology research institutes at globally renowned university medical schools. Many well-known leading experts in the global ophthalmology field, such as Professor Philip Rosenfeld, Professor David Huang, Professor Ricky Wang, and Professor Yali Jia, have become loyal users of Intalight's OCT.

With the continuous expansion of its product line and the acceleration of overseas market development, Intalight's innovative technology products will benefit more countries and regions in ophthalmology. Light every sight —— Intalight will use AI-powered modern optics to continuously surpass itself and illuminate more paths to clarity. We look forward to collaborating with leading experts in global ophthalmology to jointly spearhead breakthroughs in the diagnosis and treatment of eye diseases, providing users worldwide with more advanced technologies and solutions!

Recently, DYMUNA, the U.S. subsidiary of Dymind Biotech, was officially established. This marks an important step in Dymind Biotech's globalization strategy and demonstrates the company's confidence and commitment to the global market.

At its inception, the Dimai U.S. subsidiary held its first Innovation Forum in Miami, starting with animal healthcare. The forum shared Dimai's innovative practices in testing technology with U.S. industry peers present and promoted long-term collaboration in academic fields with local research institutions, universities, and industry associations.

All along, Dima has firmly implemented the strategy of "walking on two legs," with both domestic and international development advancing simultaneously. At the start of its overseas expansion, Dima had over 30 overseas partners, with products covering more than 20 countries and regions. Today, Dima has over 500 overseas partners, serving more than 140 countries and regions globally, with overseas revenue accounting for over 40%. Its proprietary brand has grown by more than 20% compared to last year, and the average growth in Belt and Road countries exceeds 15%.

Following the establishment of its U.S. subsidiary, subsidiaries in Russia, Italy, Mexico, and other regions are also in preparation. Meanwhile, Dima is accelerating the establishment of professional localized teams overseas, attracting global talent and resources to provide seamless communication and "zero-distance" technical services to customers while building deep collaborative relationships with local partners.

Meanwhile, Dima has established the first overseas technical training center in Indonesia, continuously empowering partner service teams through regular technical training. The second overseas technical training center by Dima is also under preparation in Peru and will officially commence operations in 2025. Additionally, Dima's Cloud Academy online English courses, multilingual training materials, and intelligent service systems have all been launched, providing comprehensive support to overseas customers and delivering exceptional customer service.

Although immune checkpoint blockade therapies (Immune Checkpoint Inhibitor, ICI) represented by PD-1/PD-L1 have been widely used in first-line treatments for more than ten types of solid tumors, their efficacy has not significantly improved. Data shows that as of 2018, the average effectiveness rate of ICI therapy in cancer patients was only 12.46%. Therefore, resistance to ICI therapy remains a major clinical challenge. Recently, the emergence of an erythrocyte-mediated enhanced immune checkpoint inhibitor drug (Erythrocyte-mediated Enhanced Immune Checkpoint Inhibitor, E-ICI) has brought new hope for curing solid tumor patients who are resistant to immunotherapy.

This E-ICI drug (WTX-212), originally developed through industry-academia-research collaboration between Westlake University and Westlake Biopharma, is the world's first red blood cell-antibody conjugate drug. By leveraging the close contact between red blood cells and the immune system within the body, engineered red blood cells are used to carry immunotherapeutic agents, efficiently activating immune cells in patients and systematically inducing an anti-tumor immune response. The results of the first-in-human clinical trial are highly encouraging, as the E-ICI drug achieved a breakthrough by realizing the world’s first complete cure of a solid tumor patient using a red blood cell-based drug. Additionally, this drug has demonstrated remarkable efficacy and safety in solid tumor patients resistant to immunotherapy, offering new hope for improving patient outcomes and enhancing quality of life.

Based on Westlake Bio's unique red blood cell engineering platform technology, Westlake Bio has developed the world's first red blood cell-antibody conjugate drug for the treatment of solid tumors—WTX-212. Leveraging the natural immune organ-targeting properties of red blood cells, WTX-212 significantly enhances the efficacy of conventional immune checkpoint drugs, emerging as a super immunotherapy (E-ICI). In its first clinical trial, this red blood cell drug demonstrated excellent safety and efficacy in patients with various solid tumors resistant to PD-1/PD-L1 immunotherapy, successfully achieving the world’s first complete cure of a solid tumor patient using a red blood cell drug. This breakthrough not only validates the immense potential of red blood cell drugs in solid tumor treatment but also brings new hope for patients with immune-resistant cancers.

Recently, the 2024 Oriental Conference of Cerebrovascular Diseases and the Annual Academic Conference of the Stroke Specialty Committee of the Shanghai Medical Association (OCIN 2024) successfully concluded in Shanghai. NEULIVE MEDICAL's braided TaminoVIA Intracranial Aneurysm Assist Coiling Stent made an appearance at this conference.

The TaminoVIA stent completed clinical research between March 20, 2022, and April 17, 2024, involving 13 research centers including Shanghai Changhai Hospital, with a successful aneurysm occlusion rate (Raymond Grade I + II) of 98.89% at 6 months post-operation. Professor Duan Guoli shared the performance of the TaminoVIA stent in clinical applications.

TaminoVIA Stent is the first domestically produced braided intracranial aneurysm assist occlusion stent in China. The entire series adopts 16-head braiding of nitinol monofilament, enhancing radial support and vessel wall apposition for smaller specification stents in the 17 system, improving the safety of treating small intracranial vessels; the stent includes four radiopaque wires, allowing for excellent visualization of the stent deployment effect during surgical procedures.